Table 4.
Summary of co-delivery of small molecule drug and siRNA by liposomes for cancer therapy.
| Delivery System | Small Molecule Drug | siRNA Target | Types of Cancer | Cell Line | Testing Stage | Ref. |
|---|---|---|---|---|---|---|
| GE-11 peptide conjugated liposome | Gemcitabine | HIF1A | Pancreatic cancer | Panc-1 |
In vitro
In vivo |
[59] |
| 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP) -based cationic liposomes | Curcumin | STAT3 | Skin cancer | B16F10 |
In vitro
In vivo |
[73] |
| PEGylated liposomes | Docetaxel | BCL2 | Lung cancer | A549, H226 |
In vitro
In vivo |
[74] |
| Galactosylated Liposomes | Doxorubicin | VIM | Hepatocellular Carcinoma | Huh7, A549 |
In vitro
In vivo |
[75] |
| Carbamate-linked cationic lipid (Cationic Liposome) | Paclitaxel | BIRC5 | Lung Cancer | NCI-H460 | In vitro | [76] |
Note: STAT3, signal transducer and activator of transcription 3; BCL2, BCL2 apoptosis regulator; VIM, vimentin; HIF1A, hypoxia inducible factor 1 subunit alpha; BIRC5, baculoviral IAP repeat containing 5.